Cost-effectiveness of becaplermin gel on wound healing of diabetic foot ulcers

Wound Repair and Regeneration

Volumn 23, Issue 3, 2015, Pages 353-360

  Gilligan, Adrienne M ^a,b   Waycaster, Curtis R ^a,b   Motley, Travis A ^c  

^a Smith and Nephew Research Centre   (United Kingdom)

^b University of North   (United States)

^c UNIVERSITY OF NORTH TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECAPLERMIN; ANGIOGENIC FACTOR; GEL; PLATELET DERIVED GROWTH FACTOR B; PLATELET-DERIVED GROWTH FACTOR BB;

ADULT; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DIABETIC FOOT; DRUG COST; DRUG PACKAGING; DRUG UTILIZATION; FEMALE; FOOT AMPUTATION; GEL; HEALTH SERVICE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL LITERATURE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT PEPTIC ULCER; WOUND CARE; WOUND HEALING; AMPUTATION; COST BENEFIT ANALYSIS; DRUG EFFECTS; ECONOMICS; MARKOV CHAIN; MIDDLE AGED; PROPENSITY SCORE; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; UNITED STATES;

AMPUTATION; ANGIOGENESIS INDUCING AGENTS; COST-BENEFIT ANALYSIS; DIABETIC FOOT; FEMALE; GELS; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; PROPENSITY SCORE; PROTO-ONCOGENE PROTEINS C-SIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNITED STATES; WOUND HEALING;

EID: 84938216381     PISSN: 10671927     EISSN: 1524475X     Source Type: Journal    
DOI: 10.1111/wrr.12285     Document Type: Article

References (49)

1. American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013; 36: 1033-46.
2. Huang ES, Basu A, O'Grady M, Capretta JC,. Projecting the future diabetes population size and related costs for the U.S. Diabetes Care 2009; 32: 2225-9.
3. Singh N, Armstrong DG, Lipsky BA,. Preventing foot ulcers in patients with diabetes. JAMA 2005; 293: 217-28.
4. Boulton AJ, Kirsner RS, Vileikyte L,. Clinical practice. Neuropathic diabetic foot ulcers. N Engl J Med 2004; 351: 48-55.
5. Philbin TM, Berlet GC, Lee TH,. Lower-extremity amputations in association with diabetes mellitus. Foot Ankle Clin 2006; 11: 791-804.
6. Stockl K, Vanderplas A, Tafesse E, Chang E,. Costs of lower-extremity ulcers among patients with diabetes. Diabetes Care 2004; 27: 2129-34.
7. Margolis DJ, Kantor J, Berlin JA,. Healing of diabetic neuropathic foot ulcers receiving standard treatment. A meta-analysis. Diabetes Care 1999; 22: 692-5.
8. Gordon KA, Lebrun EA, Tomic-Canic M, Kirsner RS,. The role of surgical debridement in healing of diabetic foot ulcers. Skinmed 2012; 10: 24-6.
9. Hehenberger K, Heilborn K, Brismar K, Hansson A,. Impaired proliferation of fibroblasts derived from chronic diabetic wounds and normal dermal fibroblasts treated with high glucose is associated with increased formation of l-lactate. Wound Repair Regen 1998; 6: 135-41.
10. Teng YJ, Li YP, Wang JW, Yang KH, Zhang YC, Wang YJ, et al., Bioengineered skin in diabetic foot ulcers. Diabetes Obes Metab 2010; 12: 307-15.
11. Steed DL, Donohoe D, Webster MW, Lindsley L,. Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. Diabetic Ulcer Study Group. J Am Coll Surg 1996; 183: 61-4.
12. Edmonds M,. The diabetic foot, 2003. Diabetes Metab Res Rev 2004; 20 (1 Suppl.): S9-12.
13. Kirsner RS, Warriner R, Michela M, Stasik L, Freeman K,. Advanced biological therapies for diabetic foot ulcers. Arch Dermatol 2010; 146: 857-62.
14. Wieman TJ, Smiell JM, Su Y,. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers: a phase III randomized placebo-controlled double-blind study. Diabetes Care 1998; 21: 822-7.
15. Margolis DJ, Kantor J, Santanna J, Strom BL, Berlin JA,. Effectiveness of platelet releasate for the treatment of diabetic neuropathic foot ulcers. Diabetes Care 2001; 24: 483-8
16. Steed DL, Attinger C, Colaizzi T, Crossland M, Franz M, Harkless L, et al., Guidelines for the treatment of diabetic ulcers. Wound Repair Regen 2006; 14: 680-92.
17. Steed DL,. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. Diabetic Ulcer Study Group. J Vasc Surg 1995; 21: 71-8.
18. ®. Directions for use. Fort Worth, TX: Smith & Nephew Biotherapeutics, Inc. 2014. Available at http://regranex.com/ (accessed June 25, 2014).
19. Heldin CH, Westermark B,. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999; 79: 1283-316.
20. Margolis DJ, Bartus C, Hoffstad O, Malay S, Berlin JA,. Effectiveness of recombinant human platelet-derived growth factor for the treatment of diabetic neuropathic foot ulcers. Wound Repair Regen 2005; 13: 531-6.
21. Kantor J, Margolis DJ,. The accuracy of using a wound care specialty clinic database to study diabetic neuropathic foot ulcers. Wound Repair Regen 2000; 8: 169-73.
22. Smiell JM, Wieman J, Steed DL, Perry BH, Sampson AR, Schwab BH,. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies. Wound Repair Regen 1999; 7: 335-46.
23. Sonnenberg FA, Back JR,. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13: 322-38.
24. Mehta SS, Suzuki S, Glick HA, Shulman KA,. Determining an episode of care using claims data. Diabetes Care 1999; 22: 1110-5.
25. Briggs AH, Ades AE, Price MJ,. Probabilistic sensitivity analysis for decision trees with multiple branches: use of the Dirichlet distribution in a Bayesian framework. Med Decis Making 2003; 23: 341-50.
26. Persson U, Willis M, Odegaard K, Apelqvist J,. The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data. Value Health 2000; 3 (1 Suppl.): S39-46.
27. Murphy SL, Jiaquan X, Kochanek KD,. Deaths: final data for 2010. Nat Vital Stat Rep 2010; 61: 1-118. Available at http://www.cdc.gov/nchs/data/nvsr/nvsr61/nvsr61-04.pdf (accessed July 9, 2014).
28. Margolis DJ, Malay DS, Hoffstad OJ, Leonard CE, MaCurdy T, Lõpez de Nava K, et al., Incidence of diabetes, diabetic foot ulcer, and lower extremity amputation among medicare beneficiaries, 2006 to 2008: data points #2. Rockville, MD: Agency for Healthcare Research and Quality, 2011.
29. Bureau of Labor Statistics Consumer Price Index. 2014. Available at http://www.bls.gov/cpi (accessed July 9, 2014).
30. U.S. Department of Health & Human Services Agency for Healthcare Research and Quality: Healthcare Cost and Utilization Project. 2014. Available at http://hcupnet.ahrq.gov/HCUPnet.jsp (accessed July 9, 2014).
31. Gorin DR, Cordts PR, LaMorte WW, Menzoian JO,. The influence of wound geometry on the measurement of wound healing rates in clinical trials. J Vasc Surg 1996; 23: 524-28.
32. Tentolouris N, Al-Sabbagh S, Walker MG, Boulton AJ, Jude EB,. Mortality in diabetic and nondiabetic patients after amputations performed from 1990 to 1995: a 5-year follow-up study. Diabetes Care 2004; 27: 1598-604.
33. Goldner MG,. The fate of the second leg in the diabetic amputee. Diabetes 1960; 9: 100-3.
34. Bodily KC, Burgess EM,. Contralateral limb and patient survival after leg amputation. Am J Surg 1983; 146: 280-2.
35. Lantis JC II, Boone D, Gendics C, Todd G,. Analysis of patient cost for recombinant human platelet-derived growth factor therapy as the first-line treatment of the insured patient with a diabetic foot ulcer. Adv Skin Wound Care 2009; 22: 167-71.
36. Frykberg RG, Zgonis T, Armstrong DG, Driver VR, Giurini JM, Kravitz SR, et al., Diabetic foot disorders. A clinical practice guideline (2006 revision). J Foot Ankle Surg 2006; 45 (5 Suppl.): S1-66.
37. Allenet B, Paree F, Lebrun T, Carr L, Posnett J, Martini J, et al., Cost-effectiveness modeling of dermagraft for the treatment of diabetic foot ulcers in the French context. Diabetes Metab 2000; 26: 125-32.
38. Margolis DJ, Allen-Taylor L, Hoffstad O, Berlin JA,. Diabetic neuropathic foot ulcers and amputation. Wound Repair Regen 2005; 13: 230-6.
39. Ghatnekar O, Persson U, Willis M, Odegaard K,. Cost effectiveness of becaplermin in the treatment of diabetic foot ulcers in four European countries. Pharmacoeconomics 2001; 19: 767-78.
40. Kantor J, Margolis DJ,. Treatment options for diabetic neuropathic foot ulcers: a cost-effectiveness analysis. Dermatol Surg 2001; 27: 347-51.
41. Albert S,. Cost-effective management of recalcitrant diabetic foot ulcers. Clin Podiatr Med Surg 2002; 19: 483-91.
42. Sibbald RG, Torrance G, Hux M, Cheryl Attard C, Milkovich N,. Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers. Ostomy Wound Manage 2003; 49: 76-84.
43. Langer A, Rogowski W,. Systematic review of economic evaluations of human cell-derived wound care products for the treatment of venous leg and diabetic foot ulcers. BMC Health Serv Res 2009; 9: 115.
44. Papanas N, Maltezos E,. Benefit-risk assessment of becaplermin in the treatment of diabetic foot ulcers. Drug Saf 2010; 33: 455-61.
45. Dougherty EJ,. An evidence-based model comparing the cost-effectiveness of platelet-rich plasma gel to alternative therapies for patients with nonhealing diabetic foot ulcers. Adv Skin Wound Care 2008; 21: 568-75.
46. Papanas N, Maltezos E,. Becaplermin gel in the treatment of diabetic neuropathic foot ulcers. Clin Interv Aging 2008; 3: 233-40.
47. Belatti DA, Phisitkul P,. Declines in lower extremity amputation in the US Medicare population, 2000-2010. Foot Ankle Int 2013; 34: 923-31.
48. Edwards J, Stapley S,. Debridement of diabetic foot ulcers. Cochrane Database Syst Rev 2010; 20: CD003556.
49. Chow I, Lemos EV, Einarson TR,. Management and prevention of diabetic foot ulcers and infections: a health economic review. Pharmacoeconomics 2008; 26: 1019-35.